Silexion Therapeutics Stock Forecast

SLXN's stock price has decreased by -97.25% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Silexion Therapeutics stock have an average target of $6.00, which predicts a 1,297.62% increase from the current stock price of 0.43.

Price Target: $6.00 (+1,297.62%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$6.00	$6.00	$6.00	$6.00
Change	+1297.6%	+1297.6%	+1297.6%	+1297.6%

Analyst Ratings

The average analyst rating for Silexion Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Mar '26	Apr '26
Strong Buy	0	0	0	1	1	1
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Naz Rahman Maxim Group	Maxim Group	Buy Reiterates $6	Buy	Reiterates	$6	+1,297.62%	Apr 29, 2026
Theodore O'Neill Litchfield Hills	Litchfield Hills	Buy Initiates $6	Buy	Initiates	$6	+1,297.62%	Dec 15, 2025

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-4.20

from -8.96

EPS Next Year

-2.27

from -4.20

Fiscal Year	FY 2012	FY 2013	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2012	Dec 31, 2013	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-	-	-	-394.93	-8.96	-4.20	-2.27
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-3.87	-2.34
Avg	-4.20	-2.27
Low	-4.46	-2.19

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.